These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma. Agarwala SS Melanoma Res; 2010 Feb; 20(1):1-10. PubMed ID: 19952852 [TBL] [Abstract][Full Text] [Related]
23. Normalization Cancer Immunotherapy for Melanoma. Vesely MD; Chen L J Invest Dermatol; 2020 Jun; 140(6):1134-1142. PubMed ID: 32092349 [TBL] [Abstract][Full Text] [Related]
24. Immunotherapy of advanced or metastatic melanoma. Cebon J; Gedye C; John T; Davis ID Clin Adv Hematol Oncol; 2007 Dec; 5(12):994-1006. PubMed ID: 18277962 [TBL] [Abstract][Full Text] [Related]
25. Advances in specific immunotherapy of malignant melanoma. Curiel-Lewandrowski C; Demierre MF J Am Acad Dermatol; 2000 Aug; 43(2 Pt 1):167-85; quiz 186-8. PubMed ID: 10906637 [TBL] [Abstract][Full Text] [Related]
26. Medical management of melanoma. Brown CK; Kirkwood JM Surg Clin North Am; 2003 Apr; 83(2):283-322, viii. PubMed ID: 12744611 [TBL] [Abstract][Full Text] [Related]
27. Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges. Millet A; Martin AR; Ronco C; Rocchi S; Benhida R Med Res Rev; 2017 Jan; 37(1):98-148. PubMed ID: 27569556 [TBL] [Abstract][Full Text] [Related]
28. A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Kottschade L; Brys A; Peikert T; Ryder M; Raffals L; Brewer J; Mosca P; Markovic S; Melanoma Res; 2016 Oct; 26(5):469-80. PubMed ID: 27306502 [TBL] [Abstract][Full Text] [Related]
35. The treatment of melanoma with an emphasis on immunotherapeutic strategies. Jack A; Boyes C; Aydin N; Alam K; Wallack M Surg Oncol; 2006 Jul; 15(1):13-24. PubMed ID: 16815006 [TBL] [Abstract][Full Text] [Related]
37. Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study. Gullo G; Rubatto M; Fava P; Brizio M; Tonella L; Ribero S; Medri M; Avallone G; Mastorino L; Fierro MT; Stanganelli I; Quaglino P Dermatol Ther; 2022 Jun; 35(6):e15492. PubMed ID: 35384181 [TBL] [Abstract][Full Text] [Related]
39. Novel Targets in Melanoma: Intralesional and Combination Therapy to Manipulate the Immune Response. Gingrich AA; Kirane AR Surg Oncol Clin N Am; 2020 Jul; 29(3):467-483. PubMed ID: 32482321 [TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies. Eggermont AM; Maio M; Robert C Semin Oncol; 2015 Jun; 42(3):429-35. PubMed ID: 25965361 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]